Tdose Binding and Tocilizumab

The investigators aim to evaluate the non-inferiority of dose-banding versus weight-based dosing of tocilizumab in patients with rheumatoid arthritis in remission or with low clinical activity, at 3 months of treatment. The secondary objectives are: To evaluate the economic benefit of dose-banding on the production of bags in the pharmacy (cost of preparing the bags), To compare the time to pharmaceutical release between the two groups, To compare the rate of bag reallocation between the two groups. This is a multicenter, prospective, randomized study evaluating the non-inferiority of administering standard doses of TOCILIZUMAB versus weight-based doses in patients with rheumatoid arthritis in remission or with low clinical activity. The patient and the clinical evaluator will be blinded. The pharmacy team performing the preparation will be open-label.

Inclusion criteria

• Diagnosis of rheumatoid arthritis according to ACR/EULAR criteria
• Rheumatoid Arthritis in low activity or remission according to DAS28
• Patient to receive a TOCILIZUMAB infusion 8mg/kg
• Patient with failure of treatment with cDMARDs or bDMARDs
• Concomitant treatment(s) for rheumatism allowed: stable doses for at least 3 months of cDMARDs, NSAIDs, analgesics, or corticosteroid therapy (< 10 mg/day of prednisone equivalent)

Exclusion criteria

• Active neoplasia
• Treatment with TOCILIZUMAB for an indication other than rheumatoid arthritis
• Treatment with TOCILIZUMAB at a dosage other than 8 mg/kg
• Diverticulitis or history of digestive perforation